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Abstract
Background: In our earlier studies 34 kDa outer membrane protein (OMP) of Shigella flexneri 2a has been identified as an
efficient immunostimulant.
Key Results: In the present study MALDI-TOF MS analysis of the purified 34 kDa OMP of Shigella flexneri 2a shows
considerable sequence homology (Identity 65%) with the OmpA of S. flexneri 2a. By using the specific primers, the gene of
interest has been amplified from S. flexneri 2a (N.Y-962/92) genomic DNA, cloned in pET100/D-TOPOH vector and expressed
using induction with isopropyl thiogalactoside (IPTG) for the first time. Immunogenicity and protective efficacy of the
recombinant OmpA has been evaluated in an intranasally immunized murine pulmonary model. The recombinant protein
induces significantly enhanced protein specific IgG and IgA Abs in both mucosal and systemic compartments and IgA
secreting cells in the systemic compartment (spleen). The mice immunized with OmpA have been protected completely
from systemic challenge with a lethal dose of virulent S. flexneri 2a. Immunization with the protein causes mild
polymorphonuclear neutrophil infiltration in the lung, without inducing the release of large amounts of proinflammatory
cytokines.
Conclusion: These results suggest that the OmpA of S. flexneri 2a can be an efficacious mucosal immunogen inducing
protective immune responses. Our findings also demonstrate that antibodies and Th1 immune response may be associated
with the marked protective efficacy of immunized mice after intranasal shigellae infection.
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Introduction
Shigellosis, an important etiological agent of bacillary dysentery
in humans is caused by Shigella, a Gram-negative bacterium which
belongs to the family Enterobacteriaceae [1]. Each year millions of
cases occur globally, with the majority occurring in children in
developing countries, and over 600,000 cases resulting in death
[2]. Antibiotics are generally effective against shigellosis, however,
the increasing level of antibiotics resistance found in Shigella
isolates, even to the newest antibiotics [3] and oral rehydration
therapy alone is not adequate in treating shigellosis has made it
necessary to develop alternate treatment and prevention strategies.
Therefore, the World Health Organization has given high priority
to the development of a safe and effective vaccine against
shigellosis [1].
Many approaches for the development of Shigella vaccines have
been attempted [4–10]. Unfortunately, no practical vaccine is
available so far. The current vaccine candidates are either not
sufficiently attenuated or immunogenic enough [5,11], demon-
strating the identification of further attenuation or novel protective
antigen is indispensable. Recently, immunoproteome analysis of S.
flexneri has shown that more protective antigens, which can be
screened from immunogenic outer membrane protein, may be
selected as vaccine candidates [12–14].
Towards vaccine approach, previously from our laboratory
among different outer membrane proteins (OMPs) of Shigella
flexneri 2a [15], the gel cut 34 kDa OMP has been identified as the
major protective antigen [16]. Recently the 34 kDa OMP of S.
flexneri 2a has been purified and characterized. It has been found
that the protein is crossreactive and antigenically conserved among
Shigella spp., the epitope is surface exposed on the intact bacterium
[17]. Upon further characterization, the protein has been shown
to stimulate macrophages through a TLR2-dependent mechanism
[18]. Moreover, 34 kDa protein has been found to up regulate the
expression of adaptor protein MyD88, p38 MAP kinase, NF-kB,
production of type-1 cytokines and chemokines as well as other
molecules (MHC II, CD40 and CD80) known to modulate the
adaptive response towards Th1 type in macrophages [18], thus
linking the innate and adaptive responses to the antigen. All these
features of the 34 kDa OMP demonstrate that this protein could
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22663successfully be used as suitable candidate for vaccine development
against shigellosis.
In our previous study, purification of the S. flexneri 2a 34 kDa
OMP to apparent homogeneity has been achieved by molecular-
sieve and ion exchange chromatographic techniques with a yield
of 100 mg per litter culture. As the yield is very low and protective
efficacy of the purified protein has not been tested in an animal
model, therefore in continuation to our previous finding [17] the
present study has been undertaken to clone and overexpress the
34 kDa OMP of S. flexneri 2a. For this purpose MALDI-TOF MS
analysis of the purified 34 kDa OMP has been performed, which
identifies the protein as OmpA of S. flexneri 2a. Based on the
corresponding ompA gene sequence of S. flexneri 2a, oligonucleotide
primers have been designed. The gene encoding the OmpA has
been amplified by PCR, cloned in pET100/D-TOPOH vector,
sequenced and expressed in BL21 Star
TM(DE3) using induction
with isopropyl thiogalactoside. The present communication also
deals with the evaluation of immunogenicity and protective
efficacy of the recombinant OmpA in mice pulmonary pneumonia
model. To understand the molecular immunological mechanism,
local and systemic antibody responses to the protein in serum and
mucosal compartment have been studied. Moreover, histology of
mice lung tissues and cytokine responses (macrophage inflamma-
tory protein-2; MIP-2, interleukin six; IL-6, interferon
gamma; IFN-c, tumor necrosis factor alpha; TNF-a) in the lung
lavage fluid have been compared among control and immunized
mice. Our results indicate that nasal immunization with the
recombinant OmpA is an effective vaccine approach to induce
protective immune responses in mice against infection by virulent
S. flexneri 2a.
Materials and Methods
Bacterial strains and culture
Shigella flexneri 2a (N.Y-962/92) was obtained from the
Pathophysiology Division of National Institute of Cholera and
Enteric Diseases, Kolkata, India.
Animal
BALB/c mice, originally obtained from Jackson Laboratories
(Bar Harbor, ME), were bred and reared in the animal facility at
the National Institute of Cholera and Enteric Diseases, Kolkata,
India. The experiments with animals were conducted in
accordance with the Animal Ethical Committee guidelines of
National Institute of Cholera and Enteric Diseases, Kolkata, India
(approval no. 18/7-6-2000).
Purification of 34 kDa OMP
34 kDa OMP was purified to apparent homogeneity from S.
flexneri 2a as described previously [17].
MALDI-TOF MS sequencing of the purified 34 kDa OMP
MALDI-TOF MS of purified 34 kDa OMP was performed to
evaluate the amino acid sequence of the full-length protein. For
this, the purified protein was reduced and alkylated with
iodoacetamide, i.e. carbamidomethylated, and digested with
trypsin that cleaves after lysine and arginine residues. The
resulting peptides were concentrated on a ZipTip micropurifica-
tion column and eluted onto an anchorchip target for analysis on a
Bruker Autoflex III MALDI TOF/TOF instrument at Alphalyse,
(Denmark). The peptide mixture was analyzed in positive reflector
mode for accurate peptide mass determination and 5–10 of the
peptides selected for analysis by MS/MS fragmentation for partial
peptide sequencing. The MS and MS/MS spectra were combined
and used for a database search in an in-house protein database
using the Mascot software.
Liposome swelling assay of 34 kDa OMP
Liposome swelling assay was carried out essentially as described
by Nikaido et al., 1991 [19], by using a mixture of acetone washed
egg phosphatidylcholine and dicetylphosphate as the phospholipid
with the 34 kDa protein. Portions (13 ml) of these liposomes and
0.6 ml of iso-osmotic L-arabinose in 5 mM Tris-HCl (pH 7.4)
were mixed rapidly in a cuvette, and the A400 was recorded.
Isolation of genomic DNA
Genomic DNA of S. flexneri 2a was prepared using the method
described by Sharma and Sing [20].
Cloning and expression of the OmpA
From the GenBank, the sequence coding for the OmpA
(Accession No. NP_836665) of S. flexneri 2a was retrieved. To
amplify the gene, the following primers were designed: F 59-
CACCATGAAAAAGACAGCTATC- 39 and R 59- TTAAGCC-
TGCGGCTGAGTTA-39. PCR amplified product was resolved
in 1% agarose gel by electrophoresis and analyzed using Gel-Doc
(Bio-Rad). The PCR amplified product of ompA gene was ligated to
commercial pET100/D-TOPOH linearized vector (Invitrogen).
Ligated product was transformed into One ShotH TOP10
chemically competent E. coli cells by heat shock. The recombinant
transformants were selected using ampicillin (100 mg/ml) on LB
agar plates. The colonies containing the recombinant plasmid was
identified and confirmed by DNA sequencing. The plasmid from
the correct transformant was isolated from an overnight culture of
recombinant E. coli Top 10 cell by using alkaline lysis protocol [21]
and then transformed into BL21 Star
TM (DE3) One ShotH
Chemically Competent E. coli cells by heat shock. The transformed
E. coli BL21 (DE3) cells harbouring the recombinant plasmid were
used in the expression study. The entire transformation reaction
was then inoculated into 10 ml LB broth containing 100 mg/ml
ampicillin and incubated overnight at 37
oC with shaking at
200 rpm. An aliquot of the overnight cell culture was added into
another tube of LB medium (containing 100 mg/ml ampicillin)
and incubated at 37uC with shaking (200 rpm). Once an optical
density at 600 nm of the cultures reached 0.5–0.8 (mid log), cells
were induced with 0.25 mM isopropyl thiogalactoside (IPTG).
Purification of protein
Recombinant protein was purified by Ni–NTA (nickel–
nitrilotriacetic acid) affinity chromatography (Qiagen) and molec-
ular sieve chromatography respectively. After induction, recom-
binant cells (0.5 g) were lysed by gentle stirring in lysis buffer (8 M
Urea; 0.1 M NaH2PO4; 0.01 M Tris–Cl; pH 8.0), centrifuged at
10,000 g for 30 min. Lysate was again mixed with 50% Ni–NTA
slurry (4:1) and kept at 4uC for 1 h. Ni–NTA slurry was loaded on
the column and finally the purified protein was eluted using
elution buffer (8 M Urea; 0.1 M NaH2PO4; 0.01 M Tris–Cl;
pH 4.5) after washing with wash buffer (8 M Urea; 0.1 M
NaH2PO4; 0.01 M Tris–Cl; pH 6.3 and 5.9). Additional purifi-
cation of the protein was achieved by using the Sephacryl S-200
HR column. The affinity purified fraction was dialysed in the
buffer 20 mM Tris-HCl (pH-8.0)-0.1 M NaCl-10 mM EDTA-0.4
% CHAPS and then applied to Sephacryl S-200 HR column pre-
equilibrated with the same buffer. The expression and purity of the
recombinant protein was confirmed by running on 10% SDS–
PAGE [22]. The lipopolysaccharide in the purified protein was
then removed as described previously [18]. The recombinant gel
OmpA as Subunit Vaccine Candidate
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toxin–removing resin and S3D peptide affinity gel columns
respectively. Absence of traces of LPS in the purified protein
was confirmed by the Limulus amoebocyte lysate chromogenic
assay with Kinetic-QCLH (Lonza). The concentration of protein
was estimated by Bradford method [23]. Purified recombinant
OmpA was then dialysed in 20 mM Tris-HCl-0.4% CHAPS-
10 mM EDTA and finally stored at 220uC for further use. This
recombinant lipopolysaccharide free protein was employed in all
the experimental methods described here.
Raising murine antisera
BALB/c mice were immunized intraperitoneally with the
recombinant OmpA emulsified with 2 volumes of Freund’s
complete adjuvant (Gibco). Two booster immunizations were
followed at an interval of 10 days and the sera were collected by
puncturing of the supraorbital plexus.
Collection of human sera
Sera were collected from blood by standard laboratory
procedure of normal human volunteers, and at day 21
(convalescent) of adult, male patients recovering from shigellosis
after admission to the Infectious Diseases and Beliaghata General
Hospital, Beliaghata, Kolkata-700 010.
Immunoblotting
The whole-cell antigens of Shigella flexneri 2a, S. boydii, S. sonnei, S.
dysenteriae type 1, enteropathogenic E. coli O115, the recombinant
induced E. coli and the recombinant his-tag OmpA were separated
by SDS-PAGE and transferred electrophoretically to nitrocellulose
membrane (Transblot; Bio-Rad Laboratories, USA) under wet
transfer condition as described previously [17]. Free sites on
nitrocellulose strips were then blocked with TBS-5% (w/v) defatted
milk (Bio-Rad) powder for overnight at 4uC. They were then
incubated sequentially with mouse antiserum (1:1000, v/v), raised
against the recombinantOmpA ofShigella flexneri2a[Forcell-lysate],
patients sera and mouseantiserum produced bychallenged with live
whole S. flexneri 2a [For OmpA] respectively in TTBS (containing
TBS with 0.1% Tween-20 and 0.5% non fat dry milk) at room
temperature for 2 h and alkaline phosphatase conjugated goat anti-
mouse IgG (1:2000, v/v[Jackson]) in TBS(containing 0.5%non-fat
dry milk) for 1 h at room temperature. Nonspecifically bound
proteins were removed by washing nitrocellulose strips with TTBS
thrice between two incubation steps. Immunoreactive bands were
visualized by color development with alkaline phosphatase using 5-
bromo-4-chloro-3 indolyl phosphate (BCIP, 3.75 mg in 250 mlo f
100% DMF [Sigma]) and nitroblue tetrazolium (NBT, 7.5 mg in
250 ml of 70% DMF [Sigma]) in carbonate buffer, pH-9.8,
containing 0.1 M NaHCO3 and 1 mM MgCl2.
Immunogenecity and protective capacity of the over
expressed his-tag OmpA
The ability of the expressed his-tag OmpA to promote an
immune response was tested in BALB/c mice. Seven-week-old
BALB/c female mice weighting approximately 25 gm were
sedated by intramuscular injection of a mixture of 0.3 mg of
xylazine hydrochloride and 1.0 mg of ketamine hydrochloride in
50 ml of saline. Each mouse was immunized intranasally with 3 mg
of recombinant his-tag OmpA or his-tag removed OmpA of
Shigella flexneri 2a on day 0, 14, and 28. A total antigen volume of
25 ml was delivered in five to six small drops applied to the
external nares with a micropipette. Control animals were
inoculated intranasally with 0.9% saline.
Three weeks (day 49) after the final immunization, all mice were
challenged intranasally with a lethal dose of S. flexneri 2a
(1610
7 CFU/30 ml) as described for the mouse lung model [24].
The mouse challenge dose was prepared from a frozen lot of S.
flexneri 2a that had been harvested during the log phase of growth,
which is the time of optimal invasiveness for shigellae, and then
stored in liquid nitrogen. Mice were monitored for weight loss,
lethargy, fur ruffling and death for 14 days after challenge. A total
of 42 mice were taken for each set of experiment. One mouse was
used as unimmunized control. All mice were then divided into two
groups. 20 mice were taken as saline immunized control and
21 mice were used for protein immunization purpose with the
recombinant protein. In the protein immunized group except one
mice (for histopathological study) all mice (20 mice) were
challenged three weeks after final immunization (day 49). Among
the 20 mice, 16 were kept for observation till fourteen days after
treatment (day 63) and 4 mice were sacrificed within 24 h of
challenged for histopathology and cytokine assay. From the saline
immunized control group of mice [20], all mice were challenged
and among these 20 mice, 16 mice were kept for observation till
fourteen days after treatment (day 63) and 4 mice were sacrificed
within 24 h of challenged for histopathology and cytokine assay.
Sampling of immune response
For antibody detection blood was taken by tail bleed from all
miceondays 0,28,42, and 63.Forcytokinestudies,lavagefluidwas
collected within 24 h of postchallenge. Pulmonary lavage was
performed by inflating the lungs with cold RPMI 1640 and by
withdrawing the fluid through trachea. Lavage fluids were
maintained at 4uC and then centrifuged to remove the cellular
debris. Sera and lavage fluids were stored at 270uC until used for
antibody and cytokine studies. Intestinal lavage (IL) fluid from mice
was collected as described previously [25]. Splenocytes for ASC
were harvested from the spleen of immunized mice by mincing and
teasing the tissue. Spleens were strained over 70 mm nylon cell
strainers. The resulting suspension of splenocytes was layered over
HistopaqueH and mononuclear cells were isolated via differential
centrifugation. The cells were then washed in RPMI 1640 with
5 U/ml penicillin G, 5 mg/ml streptomycin, and 0.1% gentamycin
and then used in enzyme-linked immunospot (ELISpot) assay.
Enzyme-linked immunosorbent assay (ELISA)
Antigen-specific antibody responses in sera and mucosal
samples were assessed by ELISA as previously described [26].
Test wells of 96-well microtitre plate (Corning, USA) were coated
with 100 ml of the recombinant his-tag protein or his-tag removed
protein sample diluted in PBS (2 mg/ml) by overnight incubation
at 4uC; blank wells were coated with buffer alone. Unbound
antigen was decanted, washed thrice with PBS (pH 7.2) -0.05%
(v/v) Tween 20. Free sites were blocked by addition of 250 mlo f
2% BSA in PBS and incubated for 2 h at room temperature (RT).
Two-fold serially diluted samples (starting from 1:32 for serum; 1:2
for lung lavage) were applied to plates and incubated at RT for
2 h. After incubation, the wells were washed with PBS containing
0.05% (v/v) Tween 20. Bound antibodies were detected by
incubation with HRP-conjugated goat anti-mouse IgG Ab or goat
anti-mouse IgA Ab. The wells were washed, colour was developed
with 100 ml of TMB (3, 39,5 ,5 9-tetramethylbenzidine) solution
(Pierce) and then kept for 15 min at RT. The reaction was stopped
by the addition of 50 mlo f1NH 2SO4 (Sigma). Absorbance was
read by a microplate reader (BIO-RAD). Endpoint titers of
OmpA-specific Abs were expressed as the reciprocal log2 of the
last dilution giving an optical density at 450 nm of 0.1 or greater.
OmpA as Subunit Vaccine Candidate
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22663ELISpot assay for detection of numbers of antibody-
secreting cells (ASCs)
Spleen cells were suspended to a density of 2.5 610
6 /ml in
complete medium consisting of RPMI 1640 supplemented with
5 U/ml penicillinG, 5 mg/ml streptomycin, 0.1% gentamycin, 10
% fetal bovine serum (Gibco). OmpA specific antibody-secreting
cells were quantitated by the method of Ndungu et al., [27] with
modifications. Briefly, the 96-well nitrocellulose bottom micro-
plates (BD Falcon) were coated with 2 mg/ml of the OmpA in
phosphate-buffered saline (PBS) and incubated at 4uC overnight.
One-hundredmicroliter volumes of the cells were allowed to
incubate for 4 h in 5 % CO2 at 37uC in the coated wells. The
plates were washed and then the wells were incubated with HRP-
conjugated goat anti-mouse IgG or IgA overnight at 4uC. Finally
the detection was carried out by the addition of the substrate
reagent (TMB) in each well. Spot-forming cells were counted
under a stereomicroscope (Olympus). Results were recorded as the
number of ASC per 10
6 splenocyte.
Histopathological analysis of tissue samples
Twenty-four hours after bacterial infection, the lung was
perfused with PBS through the abdominal aorta, removed and
fixed in 4% formaldehyde for 1 h at 4uC. The tissues were
dehydrated by gradually soaking in alcohol and xylene and then
embedded in paraffin. The paraffin-embedded specimens were cut
into 5 mm sections and stained with hematoxylin and eosin. The
sections were viewed using a digital light microscope (Olympus).
Cytokine ELISA
TNF-a, IL-6, MIP-2, and IFN-c in lung lavage were measured
in sandwich ELISA according to the manufacturer’s instruction
(R & D System).
Statistical analysis
The statistical significance of difference between the test groups
was analysed by Student’s t-test (two-tailed) using SPSS 7.5
software. Results were expressed as the mean 6 standard error of
Figure 1. Sequencing and liposome swelling assay of 34 kDa OMP and its expression analysis. A: MALDI-TOF MS of purified 34 kDa
OMP. The amino acid sequence of the 34 kDa OMP of S. flexneri 2a 2457T is given here. Peptides confirmed by MS/MS sequencing are shown in bold.
B: Swelling rate of liposomes reconstituted with S. flexneri 2a 34 kDa OMP. Different concentration of purified 34 kDa OMP of S. flexneri 2a or
denatured 34 kDa OMP by boiling in 1% SDS at 100uC were reconstituted with 3.1 mmol of egg phosphatidylcholine and 0.2 mmol of dicetyl
phosphate. Then, 13 m1 of the proteoliposome suspensions were diluted into 0.6 ml of iso-osmotic L-arabinose, and the initial rates of OD400
decrease were measured. Each point is an average of three data. C: PCR amplification of the ompA gene. Lane 1, molecular weight marker (Supermix
DNA ladder); lane 2, Shigella flexneri 2a. D: Elution profile (A280) of the Ni-NTA purified fraction on a Sephacryl S-200 HR Column. The Ni-NTA purified
fraction was applied to a column (1.8 cm by 48 cm) packed with Sephacryl S200 HR, which had been equilibrated with a buffer (20 mm Tris-HCl [pH-
8], 100 mM NaCl, 10 mM EDTA and 0.4 % CHAPS). The flow rate was 0.5 ml/min. ** indicates the elution of the purified recombinant his-tag OmpA. E:
Expression of recombinant his-tag OmpA. Lane 1, Lonza ProSieveH Color Protein molecular weight marker; lane 2, recombinant BL21 Star
TM(DE3) E.
Coli without IPTG; lane 3, recombinant BL21 Star
TM(DE3) E. Coli with 0.25 mM IPTG; lane 4, Ni-NTA purified fraction; lane 5, Sephacryl S-200 HR purified
fraction.
doi:10.1371/journal.pone.0022663.g001
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experiments. Statistical significance was assumed at p,0.05.
Results
Expression and characterization of the recombinant his-
tag OmpA
MALDI-TOF MS analysis of the 34 kDa OMP (Fig. 1A)
identified it as the outer membrane protein A (OmpA) of Shigella
flexneri 2a (sequence Identity, 65% with an e score of 4e-68) by
using Mascot (www.matrixscience.com). To confirm that the
34 kDa OMP of S. flexneri 2a is OmpA, the pore-forming activity
of 34 kDa OMP from S. flexneri 2a was determined by
reconstitution into proteoliposomes and by the osmotic swelling
of these vesicles detected by following the optical density of the
suspension. As seen in Fig. 1B, the permeability of liposomes
toward L-arabinose was proportional to the amount of 34 kDa
OMP added. From BLAST analysis the respective gene of the
OmpA of S. flexneri 2a was identified (Accession No. NP_836665)
and primer sequences were designed from the conserved domains
of the ompA gene of S. flexneri 2a. By using the primers, a DNA
fragment with a size of 1,047 bp was amplified (Fig. 1C) and
sequenced. A sequence analysis of the amplified fragment revealed
the highest homology to the ompA gene from S. flexneri 2a. The
amplicon was then cloned into pET100/D-TOPOH linearized
vector using One ShotH TOP10 E. coli as host cells. After
ampicillin selection, colonies were screened for the insert using the
same primers and PCR conditions. Finally the vector was
introduced into E. coli BL21 (DE3) cells for protein overexpression
and purification. The OmpA was expressed in BL21 Star
TM (DE3)
E. coli with N-terminal 66 histidine fusion. Following gentle
purification (Fig. 1D), the expressed protein obtain was estimated
to be approximately 37 kDa by 10% SDS-PAGE (Fig. 1E) with a
yield of 2.5 mg/litter of culture. The observed size of the
recombinant protein was slightly larger than the calculated ones
due to the presence of hexa-histidine.
Murine antiserum raised against the recombinant his-tag OmpA
recognized the whole-cell lysates of S. flexneri 2a and recombinant E.
coli (induced) as the antigen in an immunoblot analysis (Fig. 2A). It
was found that OmpA antiserum cross-reacted with the whole cell
lysates of S. boydii, S. sonnei,a n dS. dysenteriae type1 (Fig. 2B) as well as
with the whole cell antigen of enteropathogenic E. coli O115
(Fig. 2C, lane 5). Therefore, our study indicates that OmpA of S.
flexneri 2a may play important role in cross protection study. The
recombinant protein also showed reactivity with mouse antisera
produced by challenged with whole cell virulent S. flexneri 2a
(method not described here), suggesting the strong immunogenecity
of the recombinant OmpA (Fig. 2C, lane 4). This also proved that
the antigenicity of the protein is maintained.
Prevalence of antibodies to the OmpA in patients with
shigellosis
To determine whether sera from patients with shigellosis contain
antibodies to the OmpA, immunoblot analysis with the recombi-
nant his-tag OmpA preparation as the antigen was performed.
Convalescent sera (1:1000), which were collected from patients at 3
weeks after S. flexneri 2a infection, reacted specifically and intensely
with the recombinant OmpA of S. flexneri 2a (Fig. 2C, lane 1–3).
Immunogenecity and safety of expressed his-tag OmpA
in mice
To ascertain the immunogenecity and safety of the recombinant
protein in vivo, groups of mice were immunized with the protein
by the intranasal route. Death or visible side effects due to toxicity
(such as ruffled fur or lethargy) did not occur in mice immunized
with 3 mg of OmpA of S. flexneri 2a on days 0, 14, and 28.
Intranasal immunization of mice with the OmpA developed
pronounced serum IgG and IgA antibody responses to the
homologous antigen (Fig. 3A and 3B). Furthermore, no significant
difference was observed in serum IgG and IgA antibody responses
among mice immunized with recombinant his-tag OmpA or his-
tag removed OmpA (Fig. 3C and 3D), signifying that the his-tag is
not playing any important role in the measured immune response
to OmpA. The IgG titer in the lung lavage fluid of immunized
mice was significantly higher than the control mice (Fig. 3E). It was
also found that nasal administration of the recombinant his-tag
OmpA elicited significantly high levels of OmpA antigen specific
Figure 2. Characterization of the recombinant his-tag OmpA. A: Immunoblotting analysis of the OmpA using mouse polyclonal antibody
raised against the recombinant OmpA. Lane 1, Lonza ProSieveH Color Protein molecular weight marker; lane 2, recombinant BL21 Star
TM(DE3) E. Coli
with 0.25 mM IPTG; lane 3, S. flexneri 2a whole-cell lysate. B: Immunoblot analysis of whole-cell preparations of Shigella spp., with S. flexneri 2a OmpA
murine antiserum. S. flexneri 2a OmpA antiserum was used to probe the whole-cell antigen of S. flexneri 2a (lane 1), S. boydii (lane 2), S. sonnei (lane 3),
S. dysenteriae type 1 (lane 4). Molecular mass standards are noted on the left. C: Western blot analysis of recombinant his-tag OmpA of S. flexneri 2a
with convalescent-phase serum of shigellosis patients. OmpA of S. flexneri 2a was electrophoresed and transferred to nitrocellulose membrane and
finally probed with 21-day-old convalescent sera obtained from two patients (lane 1 to 3). Lane 1. Normal serum, Lane 2. Patient-1 serum, Lane 3.
Patient-2 serum. Western blot analysis of recombinant OmpA of S. flexneri 2a with antisera from virulent Shigella flexneri 2a challenged mice (lane 4)
and immunoblot analysis of recombinant his-tag OmpA antiserum with the whole-cell lysate of enteropathogenic E. coli O115 (lane 5). Molecular
mass standards are noted on the left (Lonza ProSieveH Color Protein molecular weight marker).
doi:10.1371/journal.pone.0022663.g002
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saliva, and intestinal lavage (Fig. 3F). Moreover, trafficking of
antibody-secreting B-cell lymphoblasts (ASC) to distal tissues after
final immunization was measured by using the mononuclear cells
isolated from spleen. Intranasal immunization of OmpA induced
significantly higher numbers of OmpA antigen specific IgA ASCs
in the spleen (Fig. 3G). These data demonstrate that the protein
effectively induces both systemic and mucosal immune responses
in mice.
Protective efficacy of the overexpressed his-tag OmpA of
S. flexneri 2a
Three weeks after the final immunization (day 49), all mice were
challenged with 1610
7 CFU virulent S. flexneri 2a into their
Figure 3. Recombinant OmpA elicits strong mucosal and systemic immune responses to induce protective immunity. A: Serum IgG
response in mice immunized with recombinant his-tag OmpA followed by lethal challenge with S. flexneri 2a. Mice were intranasally immunized with
recombinant his-tag OmpA or saline on days 0, 14, 28. Blood collected on days 0, 28, 42 and 2 weeks after challenge (day 63) were analysed by ELISA
for antibody levels to recombinant OmpA. The values represent the mean endpoint (log2) antibody titer 6 S.E.M. in each experimental group. The
experiment was repeated three times with similar results, p,0.05. B: Recombinant his-tag OmpA induced serum IgA response in mice immunized on
days 0, 14, 28 by the intranasal routes. Blood collected on days 0, 28, 42 and 2 weeks after challenge (day 63) were analysed by ELISA for IgA levels to
recombinant OmpA. The values represent the mean endpoint (log2) antibody titer 6 S.E.M. in each experimental group. The experiment was
repeated three times with similar results, p,0.05. C: Comparison of serum IgG response in mice immunized with recombinant his-tag OmpA or his-
tag removed OmpA of S. flexneri 2a followed by lethal challenge with S. flexneri 2a on days 0 and 63. The values represent the mean endpoint (log2)
antibody titer 6 S.E.M. in each experimental group. The experiment was repeated three times with similar results, p,0.05. D: Evaluation of serum IgA
response in mice immunized with recombinant his-tag OmpA or his-tag deleted OmpA of S. flexneri 2a followed by lethal challenge with S. flexneri 2a
on days 0 and 63. The values represent the mean endpoint (log2) antibody titer 6 S.E.M. in each experimental group. The experiment was repeated
three times with similar results, p,0.05. E: IgG levels in lung wash. Each group of mice was immunized intranasally with saline or recombinant his-tag
OmpA. Following the final immunization, lung washes were collected and then analyzed for recombinant his-tag OmpA specific IgG by ELISA. The
values shown are the mean endpoint (log2) antibody titer 6 S.E.M. in each experimental group. The experiment was repeated three times with similar
results, p,0.05. F: Intranasal immunization with the recombinant his-tag OmpA induces systemic and mucosal immune response in mice. Groups of
mice were immunized with saline or recombinant OmpA by the intranasal routes. After final immunization, lung wash, nasal wash, saliva and
intestinal lavage (IL) fluid were collected and then the levels of protein specific IgA were measured by ELISA. The values represent the mean endpoint
(log2) antibody titer 6 S.E.M. in each experimental group. The experiment was repeated three times with similar results, p,0.05. G: Analysis of
recombinant his-tag OmpA specific ASCs in mice immunized nasally with the protein. Seven days after the last nasal immunization, mononuclear cells
isolated from spleen were examined using the recombinant protein-specific ELISpot assay to determine the numbers of IgG, and IgA ASCs. The
results represent the mean values 6 S.E.M. of three independent experiments, p,0.05.
doi:10.1371/journal.pone.0022663.g003
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challenge was achieved in mice immunized with the protein
(Table 1). The saline treated control mice showed ruffled fur,
gradually become lethargic and finally death occurred within day
3 to 8 (Fig. 4). Among the saline treated control mice three mice
were survived and recovered gradually with little symptoms.
Animals received OmpA, initially (over 2 days) lost weight upon
challenge (19%) and then began to recover and gain 60% of their
pre-challenged weight by day 7. All the OmpA immunized mice
finally return to normal over the 14 day observation phase.
Histology of mouse lung tissue after S. flexneri 2a
challenge
Lungs from nonimmunized mice, from saline immunized mice
and from intranasal recombinant his-tag OmpA immunized mice
illustrated normal lung morphology (Fig. 5A, 5B, and 5C). The
recombinant his-tag OmpA immunized mice also showed normal
lung architecture, with mild infiltration of neutrophil and
mononuclear cells (Fig. 5D) after challenge with virulent S. flexneri
2a. The mice immunized with saline demonstrated significant
perivascular and peribronchial inflammation with neutrophil and
mononuclear cells, characteristic of severe pneumonia (Fig. 5E).
Cytokine levels in the lung lavage
In the present study the immunogenecity and protective efficacy
of the recombinant his-tag OmpA of S. flexneri 2a was executed in
mouse pulmonary pneumonia model. The lung is a lymphoid
organ with antigen-presenting cells, T helper and suppresser
lymphocytes, and B lymphocytes [28]. To gain deeper insight into
the biological mechanisms responsible for the superior vaccine
efficacy of OmpA, immune responses in vivo were analyzed in the
early and latter infectious stages of lung infection. Consequently,
lung lavage fluid was collected before challenge (0 h) and 6, and
24 h after intranasal challenge of both immunized and control
mice with lethal dose of virulent S. flexneri 2a. The levels of
proinflammatory cytokines, IL-6, TNF-a, IFN-c and MIP-2 in the
lavage fluid were then measured. 6 h after challenge, the levels of
MIP-2 (Fig. 6A), a key murine PMN attractant, were found to be
raised above base line in the lungs of both control and immunized
mice, with a significant more elevation in the former ones. The
level of other proinflammatory cytokine, IL-6 (Fig. 6B) was also
significantly increased with time in the lungs of control mice, but
lesser amounts were produced in the immunized mice. 6 h after
challenge, TNF-a responses (Fig. 6C) were detected in both
control and immunized mice, with higher values in the latter
animals. The levels of TNF-a began to decline after 24 h in the
immunized mice, while levels in control mice increased. IFN-c was
detectable in immunized and control mice 6 h after challenge
(Fig. 6D), with significant more elevation in immunized mice than
those in control. The levels of this cytokine began to rise in control
mice within 24 h than the immunized one.
Discussion
Shigellosis continues to be a major health concern worldwide,
occurring predominantly in children younger than five years of
age in developing countries [1]. In view of increasing antibiotic
resistance, vaccination appears to be the only rational prophylactic
approach to control shigellosis. Previously 34 kDa OMP of Shigella
flexnreri 2a has been purified and characterized as a potent
immunostimulant [17,18]. It has been reported earlier that the
amino terminal sequence of the purified protein does not match
with any known membrane protein of S. flexneri 2a [17]. Therefore,
MALDI-TOF MS of the purified 34 kDa OMP has been
performed to predict the amino acid sequence of the full-length
Table 1. Protective efficacy of the recombinant his-tag OmpA in the mouse pulmonary infection model (data representing
16 mice from each group).
Antigen
a Challenge
b #Survivors/total
c % Protection
d P-value
c
Recombinant his-tag OmpA S. flexneri 2a 16/16 100 ,0.001
0.9% saline S. flexneri 2a 3
e/16 0 -
aThe protective efficacy of the recombinant his-tag OmpA was evaluated with the mouse lethal lung model. Groups of 20 mice were immunized intranasally with the
recombinant his-tag OmpA or normal saline. Table showing the data for 16 mice from each group, as 4 mice from each group were sacrificed within 24 h after
challenge for histopathology and cytokine assay.
bThree weeks after the final immunization, mice were challenged with virulent S. flexneri 2a (N.Y-962/92).
cDeaths were recorded daily for 14 days after challenge.
d% of protection was calculated by the following formula: [(percent deaths of controls) - (percent deaths of immunized mice)]/[percent deaths of controls] 6100.
cP values were determined by the Fisher’s exact test.
eThree saline immunized control mice did not die after challenge.
doi:10.1371/journal.pone.0022663.t001
Figure 4. Mice survival rate after immunization with recombi-
nant his-tag OmpA. Two groups of 20 mice were immunized with
normal saline or OmpA. Mice were immunized intranasally at 2-week
intervals with 3 mg of OmpA in each immunization. Three weeks after
the final immunization, all animals were intranasally challenged with
1610
7 CFU of S. flexneri 2a. Figure representing the result for 16 mice
from each group, as 4 mice from each group were sacrificed within
24 h after challenge for histopathology and cytokine assay. Percent
survivors are plotted for each of 14 days postchallenge. P value,
calculated by the Fisher exact test and is ,0.001.
doi:10.1371/journal.pone.0022663.g004
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65%) to the OmpA of S. flexneri 2a. In this communication it has
been observed that the purified 34 kDa OMP of S. flexneri 2a
produces diffusion channels in liposome swelling assay, confirms
the identity of the protein as OmpA. In the present study the
OmpA of S. flexneri 2a has also been successfully cloned, over
expressed and its safety and protective activity as vaccine
candidate in mice has been assessed for the first time.
Immunization with the recombinant his-tag OmpA does not
induce severe inflammatory responses, as manifested by ruffled fur,
lethargy and death of the vaccinated mice.
Outer membrane protein A (OmpA), which is found in many
gram-negative bacteria and which was studied most extensively in
E. coli, is necessary for maintenance of structural integrity of cell
envelopes [29]. OmpA is essential for bacterial survival and
pathogenesis [30]. It is involved in bacterial conjugation [31], in
bacterial attachment, as receptors for certain bacteriophages, and
in porin activity. OmpA is also known to be associated with the
pathogenesis and plays a key role during the initial processes of
bacterial adhesion and invasion [32]. OmpA-deficient E. coli
mutants grow normally but exhibit attenuated virulence, invasive
capacity, and resistance to serum bactericidal activity [33]. OmpA
is also known to stimulate a strong antibody response [34].
Furthermore, a number of studies reveal the strong immunogene-
city of OmpA. It has been observed that recombinant OmpA of
Klebsiella pneumoniae binds to and activates both macrophages and
dendritic cells [35]. Dendritic cells activation and cytokines
production have also been found by OmpA of E. coli [36]. This
property contributes to explain its immunogenecity. Recently
Dumetz et al., demonstrates that the OmpA of Flavobacterium
psychrophilum as a possible candidate for the development of subunit
vaccine [37]. In addition, several other studies have illustrated
OmpA as a potential vaccine candidate [38–40].
In the present study protective efficacy of the recombinant
protein has been evaluated in mouse pulmonary model. The
mouse lung model has been chosen, as the pathology of
pulmonary lesions closely mirroring the colitis that characterizes
human shigellosis [41]. Our study clearly demonstrates that
intranasal immunization of mice with the recombinant his-tag
OmpA induces strong protective immunity (100%) against a lethal
challenge of S. flexneri 2a i.e. elicits strong protective immunity to
pulmonary pneumonia as well as robust levels of systemic and
mucosal immunity. Whether the recombinant his-tag OmpA of S.
flexneri 2a shows heterologous protective efficacy in other Shigella
spp., is of great interest and should be evaluated in future studies.
In order to access the immunogenicity of the recombinant his-
tag OmpA, protein specific IgG and IgA responses have been
measured. Immunization of mice result in significantly enhanced
protein specific serum and pulmonary IgG antibody responses.
The production of IgA has also been assessed, the hallmark of
mucosal immuneresponsiveness, in serum and in various mucosal
samples. Nasal administration of the protein induces significantly
higher levels of protein specific IgA production in serum and in all
of the mucosal samples tested. These results signify that the OmpA
is an efficacious mucosal immunogen for the induction of antigen-
specific systemic IgG and mucosal IgA productions. Furthermore,
trafficking antibody-secreting cells (ASCs) in the spleen has been
monitored to reflect the antibody levels in the lungs. Our result
shows that IgA-secreting cells, which have been stimulated as a
result of immunization, travel through the spleen and colonize the
Figure 5. Hematoxylin and eosin-stained light micrographs of histological sections from mice lungs (Magnifications: X10). Lungs
from nonimmunized mice (A), from saline immunized mice (B) and from intranasal OmpA immunized mice (C) showing normal airspaces,
interstitium, and bronchioles. D: Intranasal OmpA immunized mouse lung tissue, 24 h after intranasal challenge with a lethal dose of S. flexneri 2a
(1610
7 CFU/30 ml) showing mild infiltration of neutrophils and other mononuclear cells. E: Lung from saline immunized mice, 24 h after intranasal
challenge with a lethal dose of S. flexneri 2a N.Y-962/92 showing severe pneumonia with vascular congestion, peribronchial and perivascular
accumulation of inflammatory cells, including polymorphonuclear neutrophils and mononuclear cells.
doi:10.1371/journal.pone.0022663.g005
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levels of IgG-secreting cells have been detected in the spleen
although high levels of IgG have been detectable in lung lavages. It
may be possible that IgG ASC traffic predominately through
peripheral lymphoid tissues following immunization. IgA is a
critical component of the mucosal immune response and its
secretion upon mucosal immunization provides an important first
line of defense against invasion of bacterial and viral pathogens
[42,43].
In this study, we also demonstrate that antibody to the
recombinant his-tag OmpA is present in sera from patients with
shigellosis. The presence of antibody to the OmpA in convalescent
sera suggests that this OMP is potentially antigenic and elicits an
antibody response in shigellosis patients. The recombinant protein
also reacted strongly with antisera produced by challenge in mice
with live whole cell S. flexneri 2a, again indicating the strong
immunogenecity of the protein.
Histology and time kinetic study of the local cytokines
productions have also been evaluated to indicate the immune
status of the animals, at the time of challenge after immunization.
The cytokine profile of the innate immune response can influence
the profile of the subsequent specific immune response linked to
the development of immunity to shigellosis. Significantly more
elevation of MIP2 has been observed in the control mice than the
immunized mice 24 h after challenge correlates with histological
analysis showing extensive infiltration of neutrophils and mono-
nuclear cells. Massive recruitment of neutrophils has been found to
the site of Shigella infection [44]. On the contrary the mild
infiltration of PMN in the immunized mice could play crucial role
in the protective immunity by enhancing bacterial clearance [45].
A prolong elevation of TNF-a and IL-6 levels have been observed
in the control mice compared with that in the immunized mice. It
is known that high and sustained local intestinal levels of TNF-a
and IL-6 are present during established shigellosis [46,47]. In the
immunized mice the production of TNF-a and IL-6 have been
found to peak at 6 h after challenge and then decreased thereafter.
TNF-a and IL-6 are important for the early innate immune
response in bacterial infection [48]. Moreover, IL-6 activities are
critical for resolving innate immunity and promoting acquired
immune responses [49]. This transient rise of TNF-a in
immunized mice could play important role in the recruitment of
antigen presenting cells (macrophages) and upregulation of antigen
presentation as well as reflecting that Th1 response playing
prominent role in the protective immunity against lethal S. flexneri
challenge. This result is consistent with the fact that Shigella is an
intracellular pathogen. Whereas the sustained elevation of TNF-a
and IL-6 in saline treated mice corroborates with the massive
tissue damage by the infiltrating monocytes or macrophages, an
Figure 6. Time course of cytokine expression following lethal challenge of mice that had been previously immunized with
recombinant protein or saline (control). MIP-2 (A), IL-6 (B), TNF-a (C), and IFN-c (D) were assayed by ELISA with undiluted lung lavage samples.
Data represent mean 6 S.E.M. of three independent experiments with similar results, p,0.05.
doi:10.1371/journal.pone.0022663.g006
OmpA as Subunit Vaccine Candidate
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22663important characteristic of shigellosis, and ultimate death. The
level of IFN-c has also been found to increase in the lungs of both
immunized and control mice, with an earlier response in the
former animals. The rapid increase in IFN-c production observed
in lungs collected post challenge suggests that Th1 lymphocyte
activation in shigellosis may stimulate macrophages leading to the
elimination of phagocytosed Shigella organisms. In addition to
promoting Th1 responses, IFN-c serves as an effector molecule by
preventing Shigella invasion of eukaryotic cells [50]. It is therefore
tempting to speculate that this cell-mediated response, in
combination with secretory IgA, may account for the robust level
of protection against virulent S. flexneri 2a infection in the
immunized mice.
So, our current study has clearly been identified OmpA as a
potent mucosal subunit vaccine candidate. The high levels of
protein-specific IgG and IgA Ab as well as of ASCs stimulated by
intranasal administration suggest that mucosal immunization with
recombinant his-tag OmpA is an effective regimen for inducing
both systemic and mucosal immune responses in mice and for
building a two-layered defense system against Shigella infection.
Moreover, our study also reveals strong Th1 type protective
immune response in terms of IFN-c and TNF-a release. So, both
humoral and cell mediated immunity may be playing crucial role
in the OmpA induced protective immune responses.
In conclusion, we demonstrate that the expressed OmpA of S.
flexneri 2a induces strong immunogenicity and protective efficacy in
a murine model of intranasal challenge and represents a promising
and effective candidate for use in the future development of a
subunit vaccine against shigellosis in human beings.
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